Introduction
Cancer is characterized by uncontrolled cell proliferation because of genetica nd epigenetic abnormalities. [1] Epigenetics refers to the heritable changes in gene expression caused by histoneo rD NA modificationsa so pposed to alterations in the DNA primary sequence. [2] Unlike geneticc hanges, epigenetic changes are potentially reversible through modulation of epigeneticm achinery which lends itself towards therapeutic manipulation. The appreciation that cancerc an be driven above the DNA level hasc reated an opportunity to develop cancer therapeutics that modulate aberrant epigenetic states characteristic of tumor cells.
Histone modificationsr egulate the local chromatin architecture surrounding DNA sequences and are important epigenetic regulators of cell growth and proliferation. [3] Histone acetylation is ac ommon epigenetic modification andi sc ontrolled by histonea cetyltransferases and deacetylases. Histone deace-tylases (HDACs) are responsible for the deacetylation of histones which leads to compaction of the surrounding DNA regions and repression of gene transcription.A berrant HDAC activity has been associated with numerous cancers, making HDAC inhibition ap romising therapeutic target. [4] HDAC inhibition induces apoptosis in malignant cellst hrough various mechanisms, including alterations in cell cycle regulation and activation of oxidative stress pathways.
There are four classes of HDACs:c lass I( HDAC1, 2, 3, and 8), class II (HDAC4, 5, 6, 7, 9, and 10), and class IV (HDAC11) represent Zn 2 + -dependenta midohydrolases, whereas class III is composed of the mechanistically distinct NAD + -dependents irtuins. [5] Class I, II, and IV HDAC inhibitors (HDACi) consist of ac apping group that is exposed to the environment, an alkyl linker that is surrounded by ah ydrophobic tunnel, and am etal-binding moiety that is buried in the protein active site. [6] Because the metal-binding moiety,w hichi sc ritical for HDACia ctivity,i ss tructurally similar across Class I, II, and IV HDACi, modificationso ft his structural elementc an be applied to many HDACi.
Dendrimers are branched, synthetic macromolecules with controllable chemicalt opology which have been used for ab road range of biomedical applications, including drug delivery,g ene transfection, and tissue engineering. [7] Our early studies demonstrated that folic acid( FA)c onjugated to ag eneration 5( G5) polyamidoamine (PAMAM) dendrimer could target the folate receptor (FR) on cancerc ells to deliver therapeutics in vitro andi nv ivo. [8] These studies demonstrated that targeting cancer cells greatlye nhanced the efficacy and reduced the toxicityo ft he dendrimer therapeutics compared with therapeutics alone. Buildingo nt hese studies, we have improved the synthetic approach by using the highly efficient copper-Histone deacetylase inhibitors (HDACi)a re promising therapeutics for cancer. HDACi alter the epigenetic state of tumorsa nd provide au nique approach to treat cancer. Although studies with HDACi have shown promise in some cancers, variable efficacy and off-target effects have limited their use. To overcome some of the challenges of traditional HDACi, we sought to use at umor-specific dendrimer scaffold to deliver HDACid irectly to cancer cells. Here we report the design and evaluation of tumor-specific dendrimer-HDACi conjugates. The HDACi was conjugated to the dendrimer using an ester linkage through its hydroxamic acid group, inactivating the HDACiu ntil it is released from the dendrimer.Using acancercell model,wedemonstrate the functionality of the tumor-specific dendrimer-HDACic onjugates. Furthermore, we demonstrate that unlike traditional HDACi, dendrimer-HDACi conjugates do not affect tumor-associated macrophages, ar ecently recognized mechanism through whichd rug resistance emerges.W ea nticipate that this new class of cell-specific epigenetic therapeuticsw ill have tremendous potential in the treatment of cancer.
catalyzed azide-alkyne 1, 3-dipolar cycloaddition (CuAAC) as well as exploring different targeting ligandsa nd therapeuticst oo ptimize the efficacy of targeted drug delivery. [9] In this report, we describe the synthesis and biological evaluation of tumor-specific dendrimer-HDACi conjugates. We demonstrate the cell specificity ande fficacy of dendrimer-HDACic onjugates in ah uman epithelial cancer cell model and also show that the tumor-specific HDACih ave no effects on tumor-associated macrophages.
Results and Discussion
Synthesis and characterization of linker-modified suberoylanilide hydroxamic acid (SAHA) compounds and dendrimer-SAHA conjugates
In this report, we used suberoylanilide hydroxamic acid (SAHA) as ar epresentative HDACi. [10] SAHA has antitumor activity and structurale lements that are shared by many Zn-dependent HDACi. To conjugate SAHA to the dendrimer scaffold, we modified SAHA with an azido-linker through the hydroxamic acid group. The modified SAHA was attached to the alkynemodified G5 PAMAM dendrimer scaffold using the CuAAC reaction. Based on our prior work on cleavable linkers, we sought to evaluate the effects of two different linkages, an ester and an amide, on the functional properties of SAHA. [7b] The linkermodified SAHA compounds were synthesized as shown in Scheme 1. We modified SAHA with an azido-linker through either an ester bond (SAHA-eAzide 1)o ra na mide bond (SAHA-aAzide 2). The control dendrimer-HDACi conjugate (G5-eSAHA-Alkyne 5)a nd targeted dendrimer-HDACi conjugate (G5-FA-eSAHA-Alkyne 6)( Scheme 2) were synthesized using the CuAACr eaction of SAHA-eAzide 1 with the corresponding alkyne-modified dendrimers 3 and 4,respectively (Scheme 3).
The conjugates and intermediates were analyzed by matrixassisted laser desorption ionization/time-of-flight mass spectrometry (MALDI-TOF MS), high-performance liquid chromatography (HPLC), and NMR as we have previously described. [11] The number of ligands (FAa nd SAHA)a ttached to the dendrimer scaffold was obtained from the integration of the methyl protons of the terminal acetyl groupst ot he aromatic protons on the conjugated ligands. The number of acetyl groups per dendrimer was determined by computing the total number of end groups from the number average molecular weightf rom gel permeation chromatography (GPC) and potentiometric titration data for G5-NH 2 (100 %) as we have previously described. [12] The total number of end groups was appliedt ot he ratio of primary amines to acetyl groups, obtained from the 1 HNMR of the partially acetylated dendrimer,t oc ompute the average number of acetyl groups per dendrimer.
Biological evaluation of linker-modified SAHA compounds
To evaluatet he functionality of the linker-modified SAHA compounds, we used the annexin V/7-aminoactinomycin D( An/ 7AAD) apoptosis assay and the folate-receptor-overexpressing KB human cancer cell line. KB cellsw ere incubated with 100 nm of the linker-modified SAHA compounds 1 or 2 or free SAHA. After 24 h, the cells treated with the ester-linker-modified SAHA (SAHA-eAzide 1)a nd free SAHA had evidenceo f apoptosis, while the amide-linker-modified SAHA (SAHA-aAzide 2)d id not show any evidenceo fa poptosis ( Figure 1 ). To verify that the KB cell apoptosis was due to alteration of histones, Scheme1.Synthesis of SAHA-eAzide 1 and SAHA-aAzide 2. Reagentsa nd conditions:a )5-azidopentanoic acid, CMPI, DMAP,D MF,rt, 6h,1 4% (1), 20 %(2). Figure 1 . Biological evaluation of linker-modified SAHA. a) Apoptosis index demonstrating apoptosis induction with free SAHA and the ester-modified SAHA. The amide-modified SAHA did not demonstrate any evidence of apoptosis at the time points and concentrations tested. KB cells were incubated with 100 nm of the linker-modifiedSAHAcompounds and free SAHA for 24 h. Values represent the mean AE S.E.M. for n = 3i ndependent experiments. b) Protein immunoblots demonstrate that bothfree SAHAand eSAHA induce hyperacetylation of histones consistent with their knownepigenetic mechanism of action. In agreement with the apoptosis data, the amide-modified SAHA compoundd id not demonstrate any hyperacetylation of histones. KB cells were incubated with 10 mm of the SAHA compounds 2hand celllysates were collected. To tal ERK was used as the protein loading control.
we probedf or histone acetylation using protein immunoblotting. We found that free SAHA and the SAHA-eAzide 1 not only increased apoptosis, but also induced hyperacetylation of histones confirming that SAHA-eAzide 1 was still active (Figure 1 ). In contrast, the amide-modified SAHA (SAHA-aAzide 2)did not induce apoptosis or histone hyperacetylation, suggesting that this modification inactivated the SAHA molecule.
Tumor-specific uptake of dendrimer-SAHA conjugates
Because only the SAHA-eAzide 1 demonstrated therapeutic efficacy,f urther evaluations were conducted using only the ester-modified SAHA compound. Next, we wanted to compare the cell specificity of the tumor-specific dendrimer-SAHA conjugates. We and others have shown that FA-functionalized dendrimers internalize through the FR in vitro and in vivo. [14] Using our recently described in situ click reporter strategy,w e monitored the uptake of the FA-targeted and nontargeted control dendrimer-SAHA conjugates by flow cytometry. [14b] This strategy allows us to track dendrimer therapeutics after they have been delivered to cells by using CuAAC to conjugate fluorescent reporters in situ. We incubated G5-FA-eSAHA-Alkyne 6 and the nontargeted control G5-eSAHA-Alkyne 5 with KB cells for one houra t3 78 C. After incubation, the cells were washed and processed, and Alexa Fluor 647-azide (AF647) was conjugated to the internalized dendrimer conjugatesu sing the CuAAC reaction as we have previously described. [14b] The G5-FA-eSAHA-Alkyne 6 demonstrated ad ose-dependent uptake into KB cellsw hile the nontargeted G5-eSAHA-Alkyne 5 did not demonstrate any uptake ( Figure 2 ). Importantly,t he uptake of G5-FA-eSAHA-Alkyne 6 could be blockedb yp retreatment with 100 mm FA,c onfirming the FR-specificity of the tumor-targeted dendrimer-HDACi( Figure 2 ). To furtherc onfirm the cell Scheme2.Structures of PAMAM G5 dendrimer conjugates 5 and 6.
Scheme3.Synthesis of PAMAM G5 dendrimer conjugates 5 and 6. Reagents and conditions:a )1)CuSO 4 ,s odium ascorbate, SAHA-eAzide 1,u nder N 2 , o/n, 2) glycidol, rt, 6h,8 4% (5), 85 %(6).
ChemistryOpen 2015, 4,335 -341 www.chemistryopen.org specificity of the dendrimer conjugates,w eu sed our in situ click reporter strategy and confocal microscopy to demonstrate the FR-dependent uptake of the targeted-dendrimer SAHA conjugates.K Bc ells were treated as described above for one hour.A fter incubation, the KB cells were processed, and Alexa Fluor 555-azide (AF555) was conjugated to the internalized dendrimer conjugates using the CuAAC reaction. The G5-FA-eSAHA-Alkyne 6 had significantly more uptake at one hour compared with the nontargeted G5-eSAHA-Alkyne 5 (Figure 2 ).
Biological evaluation of dendrimer-SAHA conjugates
After confirming the activity of the ester-modified SAHA compound and the cell specificity of the G5-FA-eSAHA-Alkyne 6, we then evaluated the therapeutic efficacy of the dendrimer-SAHA conjugates.T he activity of HDACi depends upon its hydroxamic acid moiety and its ability to block zinc-dependent histoned eacetylases.B ased on previous studies, we hypothesized that the G5-FA-eSAHA-Alkyne 6 conjugates would target FR-overexpressing cancer cells, internalize, and hydrolyze in the endosome, allowing free SAHA to inhibith istone deacetylases andt oi nduce apoptosis. We evaluated the cytotoxicity of the dendrimer-SAHA conjugates 5 and 6 at five days. As expected, the G5-FA-eSAHA-Alkyne 6 wasm ore cytotoxic compared with the nontargeted G5-eSAHA-Alkyne 5 (Figure 2) .
One of the advantages of tumor-specific therapeuticsi st hat many cancer drugs can also affect the immune system, reducing its ability to combat tumor initiation and progression. Macrophages contribute al arge proportion of the cells in the tumor microenvironment and increased numbersa re associated with aw orse prognosis. [15] Several studies have shown that HDACia re immunosuppressive through their effects on macrophages. [16] Because of these macrophage effects, avoidance of HDAC inhibition in macrophages is desirable. To evaluatet he capacityo ft he tumor-specific HDACi to avoid clearance and effects on macrophages,w ee xamined the cytotoxic effects of free SAHA and the dendrimer-SAHA conjugates in the macrophage cell model RAW264.7. RAW264.7 cells were treated with free SAHA and the dendrimer-SAHA conjugates for 72 hours and evaluated for evidenceo fa poptosis using the An/7AAD assay mentioned above. At 72 hours, free SAHA induced apoptosis in RAW264.7 cells, while the dendrimer-SAHA conjugates had no effect, furtherc onfirming the cell specificity of the tumor-specific dendrimer-SAHA conjugates (Figure 3 ).
In this study,w eu sed the CuAACr eaction to engineer tumor-specific dendrimer HDACi and evaluated their functionality in ac ancerc ell model.T oo ur knowledge,t his is the first description of at umor-specific HDACi-an approacht hat has the potential to greatly improve the efficacy and reduce the toxicities associated with this class of epigenetic therapeutics. Additionally,w ee valuated the functional effects of modifying the metal-binding domain of HDACi with different linkers. These results provide important insights on HDACit hat will help inform the rational optimizationo ft his promising class of therapeutics.
Most HDACi are composed of three functional elements: ac apping group, ac arbon linker,a nd am etal-binding domain. We have previously demonstrated that ac leavable linker to attach at herapeutic to the dendrimer scaffold increases the efficacy of the therapeutic once it is delivered to the target cell. [7b] Building on these studies, we chose to modify the hydroxamic acidm etal-binding domain for the dual purpose of providing ac hemicalh andle to conjugate the HDACit ot he dendrimer scaffold, as well as to inactivate the HDACi while it is attached to the dendrimer scaffold. As expected, the stable amide-linker modified HDACi was nonfunctional;h owever,t he ester-linker modified HDACiw as functional and led to hyperacetylation of histones and triggered apoptosis.
Some of the biggest challenges facing traditional HDACi are limitations in efficacy and toxicities,b oth of which are at least partially due to the lack of site-specific delivery of HDACi to the desired biological targets. We and others have used biological and synthetic ligandsw ith PAMAM dendrimer scaffolds to target drugs to diseased cells and tissues. This approachn ot only improves the pharmacologic properties of the therapeutic by enhancing its circulating half-life and decreasing the offtarget effects, but this approacha lso increases the local concentration of the therapeutic in diseased cells, furthere nhancing the therapeutic efficacy.A so ur molecular understanding of cancer evolves, the toolbox of receptor-ligand combinations that can be used to facilitatet umor-specific interactions will expand, further improvingo ur ability to develop site-specific therapeutics to treat cancerand other diseases.
Conclusions
In summary,w eh ave developed at umor-specific histoned eacetylasei nhibitor (HDACi)u sing ap olyamidoamine (PAMAM) dendrimer scaffold and ar epresentative HDACi that shows cell specificity and therapeutic efficacy in ac ancer cell model.S pecifically,w eh ave shown that 1) click chemistry can be used to efficiently functionalize tumor-specific dendrimer scaffolds with HDACi, 2) the ester-modified HDACi compounds and the esterlinked dendrimer-HDACi conjugates lead to increased histone acetylation and apoptosis, and 3) the tumor-specific HDACi have no effects on tumor-associated macrophages thereby increasingtheir therapeutic efficacy on cancer cells. Further studies are ongoing to evaluate the efficacy of this tumor-specific epigenetic therapeutic in vivo.
Experimental Section 1 HNMR spectra were obtained using aV arian Inova 500 MHz (Palo Alto, USA). MALDI-TOFm ass spectra were recorded on aP EB iosystems Voyager System 6050 (Waltham, USA), using 2,5-dihydroxybenzoic acid (DHB) as the matrix. Electrospray ionization mass spectra (ESI-MS) were recorded using aM icromass Quattro II Electronic HPLC/MS/MS mass spectrometer (Waters, Milford, USA).
Materials: All solvents and chemicals were of reagent grade quality,p urchased from Sigma-Aldrich (St. Louis, USA), and used without further purification unless otherwise noted. Thin-layer chromatography (TLC) and column chromatography were performed with 25 DC-Plastikfolien Kieselgel 60 F254 (Merck, Kenilworth, USA), and Baxter silica gel 60 ( 230-400 mesh, Baxter International, Deerfield, USA), respectively.
Synthesis of G5-NHAc-Alkyne 3a nd G5-NHAc-FA-Alkyne 4. Compounds 3 and 4 were synthesized as we have previously described. [9, 11, 13] G5-NHAc-Alkyne 3 was obtained as aw hite solid; MALDI-TOFM Sm/z:3 2774 [M] + ;t he 1 HNMR-integration-determined mean number of acetyl groups per dendrimer is 80.1, and the mean number of alkyne ligands per dendrimer is 12.3. G5-NHAc-FA-Alkyne 4 was obtained as ab rown solid;M ALDI-TOFM S m/z:3 3059[M] + ;t he 1 HNMR-integration-determined mean number of FA per dendrimer is 3.5, and the mean number of free alkyne ligands per dendrimer is 8.8.
Synthesis of N 1 -((5-azidopentanoyl)oxy)-N 8 -phenyloctanediamide (SAHA-eAzide, 1) and N 1 -(5-azidopentanoyl)-N 1 -hydroxy-N 8 -phenyloctanediamide (SAHA-aAzide, 2). SAHA (50 mg, 0.19 mmol) in dimethylformamide (DMF,2mL) was added to as olution of 5-azidopentanoic acid (41 mg, 0.28 mmol), 2-chloro-1-methyl-pyridinium iodide (CMPI) (97 mg, 0.38 mmol), and 4-(dimethylamino)pyridine (DMAP) (95 mg, 0.78 mmol) in DMF (3 mL). The reaction mixture was stirred at rt for 6h.T he solvent was removed under vacuum. The residue was dissolved in CH 2 Cl 2 ,w ashed with water, dried over Na 2 SO 4 ,a nd rotary evaporated. The resulting residue was purified by column chromatography on silica gel (CH 3 OH/ CH 2 Cl 2 5:95) to give two isomers SAHA-eAzide 1 and SAHA-aAzide 2 as white solids, 1 (10 mg, 14 %) and 2 (14 mg, 20 %); Synthesis of G5-eSAHA-Alkyne 5. G5-NHAc-Alkyne 3 (10 mg, 0.31 mmol) was dissolved in CuSO 4 (10 mol %p er SAHA-eAzide, 1.0 mg mL À1 H 2 O) and sodium ascorbate (60 mol %p er SAHA- Figure 3 . Biological evaluation of the dendrimer SAHA conjugates in tumorassociated macrophages. RAW264.7 cells treated with 1 mm free SAHA showed significantly greater levels of apoptosis than RAW264.7 cells treated with the dendrimer-SAHA conjugates confirmingt he tumor-specificity of targeted dendrimer-SAHA conjugates. RAW264.7 cells were incubated with dendrimer SAHA conjugates and free SAHAfor 3dand assessed for apoptosis using the annexin/7AAD assay.V alues represent the mean AE S.E.M. for n = 3i ndependent experiments.
ChemistryOpen 2015, 4,335 -341 www.chemistryopen.org eAzide, 1.0 mg mL À1 H 2 Os olution) solution. SAHA-eAzide 1 (7.5 azide mole ratio to G5-NHAc-Alkyne 3,5 .0 mg mL À1 DMSO solution) was added. The reaction mixture was stirred at rt under N 2 o/n. Glycidol (10 mL) was added to cap the remaining free amino groups on the dendrimer surface, and the reaction mixture was stirred at rt for 6h.Samples were purified using 10 000 MWCO centrifugal filtration devices. The purification consisted of ten cycles (5 PBS and 5 deionized H 2 O) at 4800 rpm for 20 min each. The purified dendrimer conjugates were lyophilized to yield 5 as white solids (9.1 mg, 84 %);M ALDI-TOFM Sm/z:3 4722 [M] + ;t he 1 HNMRintegration-determined mean number of SAHA-eAzide molecules is 4.0.
Synthesis of G5-FA-eSAHA-Alkyne 6. G5-NHAc-FA-Alkyne 4 (10 mg, 0.30 mmol) was dissolved in CuSO 4 (10 mol %p er SAHAazide, 1.0 mg mL À1 H 2 O) and sodium ascorbate (60 mol %p er SAHA-azide, 1.0 mg mL À1 H 2 Os olution) solution. SAHA-eAzide 1 (7.5 azide mole ratio to G5-NHAc-FA-Alkyne 4,5 .0 mg mL À1 DMSO solution) was added. The reaction mixture was stirred at rt under N 2 o/n. Excess glycidol (10 mL) was added to cap the remaining free amino group on the dendrimer surface. The reaction mixture was stirred at rt for an additional 6h.S amples were purified using 10 000 MWCO centrifugal filtration devices. The purification consisted of ten cycles (5 PBS and 5 deionized H 2 O) at 4800 rpm for 20 min each. The purified dendrimer samples were lyophilized to yield 6 as brown solids (9.1 mg, 84 %);M ALDI-TOFM Sm/z:3 5921 [M] + ;t he 1 HNMR-integration-determined mean number of SAHA-eAzide molecules is 3.2.
Cell culture: KB cells, ah uman cancer cell model (American Type Culture Collection, ATCC, Manassas, USA), were maintained as am onolayer cell culture in FA-free Roswell Park Memorial Institute (RPMI) 1640 medium (Life Te chnologies, Grand Island, USA) supplemented with 10 %f etal bovine serum (FBS), 100 UmL À1 penicillin, and 100 mg mL À1 streptomycin. The cell cultures were incubated at 37 8Cw ith 5% CO 2 .R AW264.7 cells were cultured at 37 8Ci nahumidified atmosphere of 5% CO 2 and 95 %a ir,i nR PMI 1640 medium containing 10 %F BS supplemented with penicillin (100 units mL À1 )and streptomycin (100 gmL À1 ).
Apoptosis assay and flow cytometry:
In preparation for flow cytometry,K Bc ells were plated in 12-well plates and grown to 50 % confluency.C ells were washed with warm divalent cation-free PBS (1 mL) before the addition of new medium. All cells treatments were performed using the culture medium. After the indicated incubation times, the cells were washed with warm divalent cationfree PBS (1 mL) and immediately resuspended in culture medium, centrifuged at 1500 rpm for 5min, and washed with FBS-free media. The resulting pellet was resuspended in annexin binding buffer (100 uL, BioLegend, San Diego, USA) containing a1:100 dilution of both stock Alexa Fluoro 647 annexin (BioLegend, San Diego, USA) and 1mgmL À1 7-aminoactinomycin D( Sigma Aldrich, St. Louis, USA) for 15 min in the dark. Cells were washed twice with cell culture media to remove any nonspecifically bound dye, followed by resuspending the pellet in annexin Vb inding buffer (200 uL) for flow cytometric?a nalysis. 50 000 events were collected using an Accuri C6 Flow Cytometer (Accuri Instruments, Inc.,A nn Arbor,U SA) and analyzed using FlowJo software version 7.6.5 (Tree Star Inc.,Ashland, USA).
Protein immunoblotting: Cells were harvested and lysed using radioimmunopreciptation assay (RIPA) buffer containing 25 mm Tris-HCl, pH 7.6, 150 mm NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1mm Na 3 VO 4 and 10 mm NaF (phosphatase inhibitors), and 0.1 %S DS with 10 mLo fH alt Protease Inhibitor Cocktail (Pierce, Rockford, USA) added for each 1mLo fb uffer.S amples were separated using sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to ap olyvinylidede fluoride (PVDF) membrane. PVDF membranes were blocked with 0.1 % BSA/0.1 %T ween-20 in tris-buffered saline (TBS, blocking buffer) and washed with blocking buffer.P VDF membranes were then probed with rabbit antibodies against acetylated histone 3( 1:500 for 1h)o rt otal extracellular-signal-regulated kinase 1( ERK1, 1:1000 for 1h,S anta Cruz Biotechnology;S anta Cruz, USA). Alkaline-phosphatase-conjugated goat anti-rabbit secondary antibodies (Thermo Scientific, Waltham, USA) were used at adilution of 1:20000 and incubated for 1h.
Statistics: Data were analyzed by Student'st -test using GraphPad 6.01 statistical software (GraphPad Software Inc.,S an Diego, USA).
